Drugs / Azelnidipine
Azelnidipine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT01819441 | May 2012 → Dec 2016 | cerebrovascular disorder | Yining Huang | Unknown | No outcome recorded |
| Phase 4 | NCT00607035 | May 2006 → Apr 2008 | hypertensive disorder | Jichi Medical University | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 4 | NCT00454662 Comparator | Apr 2007 → Sep 2011 | diabetes mellitus, hypertensive disorder | COLM Study Research Organization | Completed | No outcome recorded |
| Phase 4 | NCT00294567 Comparator | Dec 2005 → May 2009 | coronary atherosclerosis, hypertensive disorder | Juntendo University | Completed | No outcome recorded |
| Phase 4 | NCT00134160 Comparator | Aug 2005 → May 2010 | hypertensive disorder | OSCAR Study | Completed | No outcome recorded |
| — | NCT01028534 Comparator | Jul 2010 → Dec 2013 | hypertensive disorder, obstructive sleep apnea syndrome | Kyoto University, Graduate School of Medicine | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2010-01-20 | Daiichi Sankyo | Regulatory Daiichi Sankyo Receives Approval to Manufacture and Market Rezaltas(R) Combination Tablets to Treat Hypertension daiichisankyo.com ↗
Daiichi Sankyo Company, Limited (hereafter; Daiichi Sankyo) today announced that it has received approval in Japan to manufacture and market Rezaltas® combination tablets LD and HD for the treatment of hypertension. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2010-01-20 | Daiichi Sankyo | Daiichi Sankyo Receives Approval to Manufacture and Market Rezaltas(R) Combination Tablets to Treat Hypertension daiichisankyo.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | azelnidipine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00454662 ↗ |
| Known as | Azelnidipino | ChEMBL registry synonym — accepted as the source's own label CHEMBL1275868 ↗ |
| Known as | Calblock | “effects of long-term administration of Calblock (azelnidipine) on plaque volume will be determined quantitatively by 3D-IVUS” NCT00294567 ↗ |
| Known as | CS-905 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1275868 ↗ |
| Action | Inhibit | “calcium channel blocker” NCT00454662 ↗ |
| Modality | Small molecule | — CHEMBL1275868 ↗ |